Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Vaccines: engineering immune evasion.

Mascola JR.

Nature. 2006 May 11;441(7090):161. No abstract available.

PMID:
16688158
2.

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH.

Nature. 2006 May 11;441(7090):239-43. Epub 2006 Apr 16.

PMID:
16625206
3.

Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.

Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, Stoff-Khalili MA, Waehler R, Hsu HC, Li Z, Li J, Mountz JD, Wu H, Curiel DT.

Virol J. 2008 Aug 21;5:98. doi: 10.1186/1743-422X-5-98.

4.

Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC.

J Clin Invest. 2007 Dec;117(12):3958-70.

5.

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.

Dicks MD, Spencer AJ, Coughlan L, Bauza K, Gilbert SC, Hill AV, Cottingham MG.

Sci Rep. 2015 Nov 18;5:16756. doi: 10.1038/srep16756.

7.

T-cell immunity generated by recombinant adenovirus vaccines.

Yang TC, Millar JB, Grinshtein N, Bassett J, Finn J, Bramson JL.

Expert Rev Vaccines. 2007 Jun;6(3):347-56. Review.

PMID:
17542750
8.

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J.

J Gen Virol. 2006 Aug;87(Pt 8):2135-43.

PMID:
16847108
9.

Prospects for oral replicating adenovirus-vectored vaccines.

Deal C, Pekosz A, Ketner G.

Vaccine. 2013 Jul 11;31(32):3236-43. doi: 10.1016/j.vaccine.2013.05.016. Epub 2013 May 22. Review.

10.

Generation of Lymphocytic Choriomeningitis Virus Based Vaccine Vectors.

Ring S, Flatz L.

Methods Mol Biol. 2016;1404:351-64. doi: 10.1007/978-1-4939-3389-1_24.

PMID:
27076310
11.

Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG, Worgall S.

J Virol. 2006 Jun;80(11):5523-30.

12.

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.

Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJ, Barouch DH.

J Virol. 2006 Dec;80(24):12009-16. Epub 2006 Oct 11.

13.

Immune responses of two recombinant adenoviruses expressing VP1 antigens of FMDV fused with porcine granulocyte macrophage colony-stimulating factor.

Du Y, Jiang P, Li Y, He H, Jiang W, Wang X, Hong W.

Vaccine. 2007 Nov 28;25(49):8209-19. Epub 2007 Oct 15.

PMID:
17980939
15.

The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector.

Millar J, Dissanayake D, Yang TC, Grinshtein N, Evelegh C, Wan Y, Bramson J.

Cell Immunol. 2007 Nov-Dec;250(1-2):55-67. doi: 10.1016/j.cellimm.2008.01.005. Epub 2008 Mar 3.

PMID:
18313652
16.

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.

Zaiss AK, Muruve DA.

Gene Ther. 2008 Jun;15(11):808-16. doi: 10.1038/gt.2008.54. Epub 2008 Apr 3. Review.

PMID:
18385765
17.

HLA and the Ad5/HIV STEP trial.

[No authors listed]

Hum Gene Ther. 2011 May;22(5):517. doi: 10.1089/hum.2011.4110. No abstract available.

PMID:
21521071
18.

Protective immunity against porcine circovirus 2 by vaccination with ORF2-based DNA and subunit vaccines in mice.

Shen HG, Zhou JY, Huang ZY, Guo JQ, Xing G, He JL, Yan Y, Gong LY.

J Gen Virol. 2008 Aug;89(Pt 8):1857-65. doi: 10.1099/vir.0.2008/000125-0.

PMID:
18632956
19.

Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF.

Worgall S, Krause A, Qiu J, Joh J, Hackett NR, Crystal RG.

J Virol. 2007 Dec;81(24):13801-8. Epub 2007 Oct 17.

20.

Engineered adenovirus serotypes for overcoming anti-vector immunity.

Dharmapuri S, Peruzzi D, Aurisicchio L.

Expert Opin Biol Ther. 2009 Oct;9(10):1279-87. doi: 10.1517/14712590903187053. Review.

PMID:
19645630

Supplemental Content

Support Center